Welcome to our dedicated page for Avita Medical SEC filings (Ticker: RCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scrolling through Avita Medical’s dense SEC documents to verify RECELL sales momentum or new FDA milestones can drain hours. Clinical trial disclosures, royalty triggers, and share issuances are scattered across multiple forms, and insider trading activity often arrives without context.
Stock Titan solves this complexity. Our AI-powered summaries turn the most technical statements in an Avita Medical annual report 10-K simplified, each Avita Medical quarterly earnings report 10-Q filing, and every Avita Medical 8-K material events explained into clear, plain-English insights. Need real-time alerts? The platform delivers Avita Medical Form 4 insider transactions real-time, so you can spot executive stock moves the moment they hit EDGAR.
Here’s what you can expect:
- 10-K & 10-Q – Track RECELL revenue by indication, R&D spend, and cash runway with Avita Medical earnings report filing analysis.
- 8-K – Understand material events like FDA guidance letters or pivotal trial updates in minutes.
- Form 4 – Follow Avita Medical insider trading Form 4 transactions to gauge management’s confidence.
- DEF 14A – Review Avita Medical proxy statement executive compensation without wading through legal language.
Whether you are understanding Avita Medical SEC documents with AI for the first time or comparing quarters, our real-time feed and expert commentary surface the details that matter—RECELL adoption rates, clinical spend, and any executive stock transactions Form 4 that could signal future direction. No more searching form by form; the answers are already highlighted, explained simply, and updated the instant the company files.
Avita Medical director Robert McNamara reported a personal purchase of company stock on 08/28/2025. The Form 4 shows a purchase of 10,000 shares of Avita Medical common stock at $4.50 per share. After the transaction he beneficially owns 86,771 shares, a figure the filing notes includes unvested restricted stock units. The filing identifies McNamara as a director and was signed by an authorized power of attorney on 08/29/2025. The document lists no derivative transactions and provides no additional financial results or forward-looking statements.
Insider purchase reported: Avita Medical (RCEL) CFO David O'Toole purchased 2,000 shares of the company's common stock on 08/26/2025 at a price of $4.52 per share. After the transaction he beneficially owns 31,657 shares in a direct capacity. The filing shows no amendments and no derivative transactions were reported.
Avita Medical, Inc. (RCEL) director Robert McNamara reported a purchase of 10,000 shares of the company's common stock on 08/19/2025 at a price of $5.00 per share, bringing his beneficial ownership to 76,771 shares. The Form 4 was signed by power of attorney on 08/20/2025.
David O'Toole, identified as the Chief Financial Officer, filed a Form 4 reporting a change in beneficial ownership of Avita Medical, Inc. (RCEL). The filing shows he acquired 2,000 shares of common stock on 08/12/2025 at a price of $4.81 per share, increasing his direct holdings to 29,657 shares. The transaction is reported under transaction code P and the Form 4 was filed by one reporting person.
AVITA Medical, Inc. filed a Current Report on Form 8-K dated August 12, 2025, reporting that the company issued a press release announcing the successful completion of an equity raise in Australia. The filing states the press release is attached as Exhibit 99.1 and clarifies that the information furnished, including the exhibit, is not "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated. The 8-K is signed by Chief Financial Officer David O'Toole. The company's common stock trades under the symbol RCEL on Nasdaq.
AVITA Medical, Inc. has filed a Form S-8 to register an additional 2,500,000 shares of common stock under its 2020 Omnibus Incentive Plan following stockholder approval on June 4, 2025. The filing also registers an aggregate of 605,902 shares that are issuable upon exercise or vesting of previously approved awards, comprised of 545,770 stock options and 60,132 restricted stock units.
The registration incorporates by reference prior S-8 filings and recent SEC reports, including the Annual Report for the year ended December 31, 2024 and quarterly reports for the quarters ended March 31, 2025 and June 30, 2025. The filing describes indemnification provisions under Delaware law, charter and bylaw exculpation language, indemnification agreements with directors and officers, and directors' and officers' liability insurance.
AVITA Medical (Nasdaq: RCEL; ASX: AVH) is issuing 400,000 new common shares to two OrbiMed-affiliated lenders in lieu of cash as consideration for a Fifth Amendment to its $40 million secured Credit Agreement. The shares will be delivered on or about 8 Aug 2025; no cash proceeds will be received.
The amendment reduces near-term revenue covenants that trigger mandatory principal amortisation, giving AVITA greater flexibility during FY-25/26 while it scales its FDA-approved RECELL wound-care platform. If future revenue again falls short, the company must repay 5 % of outstanding principal each quarter and pay related fees. Debt remains secured against substantially all assets and is exposed to rising rates.
Following the issue, total basic share count will rise modestly (≈1.5 % based on ~26 M shares outstanding), causing limited dilution. AVITA remains an Emerging Growth Company and does not expect to pay dividends. Key risks disclosed include covenant breach, liquidity pressure, equity volatility and macroeconomic factors.
AVITA Medical, Inc. (RCEL) filed an 8-K announcing a Fifth Amendment to its October 18 2023 Credit Agreement with OrbiMed affiliates. The amendment lowers trailing-12-month revenue covenants for the next four quarters to $73 m (Q3-25), $77 m (Q4-25), $90 m (Q1-26) and $103 m (Q2-26). The original $115 m covenant is reinstated from Q3-26 through the debt’s maturity.
In consideration, the Company will issue 400,000 registered common shares to the lenders, using its effective Form S-3 shelf. All other terms of the credit facility remain unchanged.
Item 2.02 notes release of Q2-25 financial results via Exhibit 99.1, but the filing itself does not include those figures.
FAQ
What is the current stock price of Avita Medical (RCEL)?
What is the market cap of Avita Medical (RCEL)?
